

**A Retrospective Study On Clinical Features Of
Early Neonatal Jaundice In Term Babies At
Ratchaburi Hospital, Thailand**

ABSTRACT

Background: Neonatal jaundice is a common condition that sometimes leads to devastating neurological consequence such as kernicterus. This study was aimed to find out the clinical features and etiology of neonatal jaundice in term newborn admitted to Ratchaburi Hospital.

Aim: This study was aimed to recognize clinical features and to know etiology of term neonatal jaundice.

Study design: Hospital-based retrospective study

Methodology: The study was conducted by reviewing 117 medical records of neonatal jaundice who were admitted at Ratchaburi Regional Hospital, Bangkok, Thailand from 1st October 2007 to 30th September 2008. Both the patient's and their mother's profiles, etiology and clinical features of jaundice were extracted.

Results: The results showed that female babies were more likely to develop jaundice. The most common etiology was inconclusive jaundice (64.9%) followed by ABO incompatibility (17.9%) and breastfeeding jaundice (10.2%)., Other less common causes were G6PD deficiency, minor blood group incompatibility and cephalhematoma. The onset of neonatal jaundice usually occurred on the 2nd to the 4th day of life and almost all newborns responded well to phototherapy. Most of the interventions were started on the 2nd day of life. Moreover, exchange transfusion was needed in four cases. **CONCLUSION: FROM OUR STUDY, THE MOST COMMON ETIOLOGY WAS INCONCLUSIVE JAUNDICE WHICH IS FOLLOWED BY ABO INCOMPATIBILITY BUT NON-IMMUNE HEMOLYSIS AND POLYCYTHEMIA WERE NOT ENCOUNTERED. THERE WAS SIGNIFICANT DIFFERENCE OF HAEMATOCRIT, NRC AND RETICULOCYTES BETWEEN HAEMOLYTIC AND NON-HAEMOLYTIC GROUPS. DETAILED APPROACH OF HISTORY TAKING AND PHYSICAL EXAMINATION, EARLY INVESTIGATIONS OF JAUNDICE WORK UP AND SEPTIC WORK UP ARE RECOMMENDED IN ELICITING VARIOUS ETIOLOGIES AND PREVENTING COMPLICATIONS.**

Keywords: Neonatal jaundice, etiology, clinical feature, retrospective

1. INTRODUCTION

The most common cause of readmission to hospital in healthy term infants is neonatal jaundice [1]. Paediatricians were aggressive in treating jaundice though several factors have changed the management of jaundice [2, 3]. Effective approach and evaluations for management are crucial in preventing bilirubin-induced encephalopathy and long term neurodevelopment outcomes [4]. The possible factors exaggerating physiological jaundice are shown in table 1 [5].

25

26

Table 1: Possible factors exaggerating physiological jaundice

Factor	Clinical correlate
1. Bilirubin load to liver	<ul style="list-style-type: none"> • Infants with polycythemia • Infants of a diabetic mother • Collection of extravasated blood like cephalhematoma and intraventricular haemorrhage • Delayed cord clamping
2. Defective uptake from liver	<ul style="list-style-type: none"> • Decreased Y protein due to caloric deprivation
3. Defective bilirubin conjugation	<ul style="list-style-type: none"> • Due to decreased UDPG activity as seen in hypothyroidism and inhibitors in breast milk
4. Deceased hepatic excretion	<ul style="list-style-type: none"> • Congenital infections
5. Inadequate hepatic perfusion	<ul style="list-style-type: none"> • Hypoxia • Congenital heart diseases
6. Increased enterohepatic circulation	<ul style="list-style-type: none"> • Unfed babies • Delayed passage of meconium

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

Studies in the 1980s and 1990s suggested that kernicterus from jaundice was rare and that too many infants were being treated unnecessarily [6, 7]

Early detection, effective intervention and new approaches to prevention have been also stimulated as it has potential damage to developing brain [8]. Previous studies have indicated a relationship between neonatal hyperbilirubinemia and diverse factors including racial region, male gender, epidural anaesthesia, and instrumental delivery [9].

Risk factors for significant neonatal hyperbilirubinemia are:

1. Jaundice visible on the first day of life
2. A sibling of jaundice or anaemia
3. Unrecognized haemolysis (ABO, Rh and another blood incompatibility)
4. Nonoptimal feeding (Formula or breastfeeding)
5. Deficiency of glucose 6 phosphate dehydrogenase
6. Infection, Infant of diabetic mother and immaturity
7. Cephalhematoma or bruise, Central haematocrit >65% (polycythemia)
8. East Asian, Mediterranean, Native American heritage [10].

Pathological Jaundice fulfils any of the following criteria:

1. Clinical jaundice appearing in the first 24 hours.
2. Increase on the level of total bilirubin by more than 0.5 mg/dL/hr or 5mg/dL/24 hr.
3. Total serum bilirubin > 12 mg/dL in term infants and total serum bilirubin level 10- 14 mg/dL in preterm infants (Almeida, 2004).
4. Direct reacting bilirubin > 2.0 mg/dL [11].

The primary concern with respect to exaggerated hyperbilirubinemia is the potential for neurotoxic effects, but general cellular injury also occurs [12]. Bilirubin can interfere with neuroexcitatory signals, impair nerve conduction (particularly auditory nerve) inhibition exchange and water transport in renal cells. The infections, acidosis, hypoxia, sepsis, prematurity and hyperosmolarity can cause blood-brain barrier more susceptible to the entry of bilirubin [13].

Risk factors of severe hyperbilirubinemia: [14]

- 59 *Major Risk Factors:*
60 1. Pre-discharge micro bilirubin level in the high-risk zone
61 2. Jaundice observed in 1st 24 hour
62 3. Blood group incompatibility with a positive direct antiglobulin test, another known
63 haemolytic disease
64 4. The previous sibling received phototherapy
65 5. Cephalhematoma or significant bruising
66 6. Exclusive breastfeeding if nursing is not going well and obesity
67 7. East Asian Race

- 68 *Minor Risk Factors:*
69 1. Pre-discharge micro bilirubinemia level in the high intermediate risk zone
70 2. Jaundice observed before discharge
71 3. Previous sibling with jaundice
72 4. Macrosomic infant of a diabetic mother
73 5. Male Gender

74 *Factors associated with decreased risk of neonatal jaundice*

- 75 1. Microbilirubin level in the low-risk zone
76 2. Exclusive bottle feeding
77 3. Black race
78 4. Discharge from the hospital after 72 hour


79
80 Although hazardous hyperbilirubinemia ($\geq 30\text{mg/dL}$) is uncommon, timely recognition,
81 potent work up and compelling management play pivotal roles in the prevention of chronic,
82 bilirubin-induced neurotoxicity [15]. This study aimed to document the clinical profiles and
83 aetiology of early neonatal jaundice.

84
85 **2. MATERIAL AND METHODS**

86
87 This study was a hospital-based retrospective record study of 117 medical records,
88 conducted at Ratchaburi regional hospital, Bangkok, Thailand from November 2008 to 2009
89 March. The clinical features of early neonatal jaundiced for newborns younger than 7 days
90 whose gestational age ranges from 37 to 42 weeks were explored and the onset of jaundice
91 within 7 days requiring intervention for jaundice was studied. The sample size was
92 calculated using the formula for single population proportion with the margin of error 10%,
93 the assumption of 95% confidence level [20] and prevalence of 60% of known etiology of
94 neonatal jaundice in all pathological jaundice in Ratchaburi Regional Hospital. The minimum
95 sample size required was 92. The exclusion criteria included preterm, low birth weights,
96 major congenital anomalies and congenital infections, systemic infections before the onset of
97 jaundice, serious illness such as sepsis, meconium aspiration syndrome, and severe birth
98 asphyxia.
99 Required data from the selected records were collected and transferred into case record
100 forms that are constructed based upon the variables from Ratchaburi Regional Hospital and
101 study objectives. The data obtained were calculated by SPSS version 11.5 for statistical
102 analysis. The research was funded by the Faculty of Tropical Medicine, Mahidol University,
103 Thailand in collaboration of SEAMEO TROPED, Thailand.

104
105 **3. RESULTS**

106
107 Figure 1 shows that jaundice was the most common etiology in this study ($n=76$, 64.9%),
108 which was followed by ABO incompatibility (17.9%). Other diagnoses were breastfeeding
109 jaundice (10.2%), G6PD deficiency (4.2%) and minor blood group incompatibility (1.7%).
110 There was one case of cephalhematoma. There were no cases of non-immune haemolysis
111 and polycythemia in this study.



112
113
114
115

Figure 1: Etiologies of Jaundice

Table 2: Characteristic maternal profile according to the etiology of jaundice

Maternal profile	No.	Blood group incompatibility		G6PD def. (n=5)	Breastfeeding (n=12)	Cephal-hematoma (n=1)	Inconclusive (n=76)
		ABO (n=21)	Minor (n=2)				
Maternal age (n=113)							
15-20 years	26	5	0	0	1	0	20
21-35 years	76	15	2	5	7	1	47
36-45 years	11	1	0	0	4	0	6
Maternal complication (n=116)							
CPD	18	5	0	1	1	0	11
Hypertension	2	0	0	0	0	0	2
Diabetic	1	0	0	0	1	0	0
Hypertension and diabetic	1	0	0	0	0	0	1
No complication	94	16	2	3	10	1	62
Oxytocin using (n=115)							
Yes	3	0	0	0	0	0	3
No	112	21	2	5	11	1	72
Any medication during pregnancy (n=115)							

Yes	2	0	0	0	1	0	1
No	113	21	2	4	11	1	74

Previous neonatal jaundice history (n=67)

Yes	5	0	0	0	1	0	4
No	62	13	0	4	5	1	39

116

117

118

119

120

121

122

123

124

125

Table 2 shows that 47/76 cases (62%) born to mothers aged between 21 to 35 years were diagnosed as inconclusive jaundice. In this study, oxytocin was used in 3 mothers and diagnoses of their infants were inconclusive jaundice. Among 5 cases that had the previous history of neonatal jaundice, 1 case was breastfeeding jaundice and other 4 cases were inconclusive jaundice. Other findings such as bruise/petechiae, hepatosplenomegaly were not observed in this study.

Table 3: Maximum bilirubin level according to the etiology of jaundice

Maximum bilirubin level	No.	Blood group incompatibility		G6PD def. (n=5)	Breastfeeding (n=12)	Cephal-hematoma (n=1)	Inconclusive (n=76)
		ABO (n=21)	Minor (n=2)				
Maximum micro bilirubin level (mg/dL)							
<12	5	0	0	0	1	0	4
12-25	106	21	2	5	11	1	66
>25	6	0	0	0	0	0	6
Maximum unconjugated bilirubin level (mg/dL)							
<12	10	1	0	0	1	0	8
12-25	103	20	2	5	11	1	64
>25	4	0	0	0	0	0	4

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

Most of the case had the maximum micro bilirubin level in range 12-25 mg/dL. Similarly, the majority of the cases had a maximum unconjugated bilirubin level of 12-25 mg/dL. All cases that had bilirubin level above 25 were in inconclusive etiology. (Table 3)

Table 4 shows the mean values of CBC profile and bilirubin levels according to etiology of hyperbilirubineemia. Maximum mean hematocrit (58.3%) was seen in babies with breastfeeding jaundice. In all diagnosis, the mean value of WBC and platelet count were within normal limit. NRC was found in only ABO incompatibility and inconclusive jaundice and higher mean of NRC in ABO incompatibility (131.5%). Mean of reticulocyte count percentage was 13.6 in minor blood group incompatibility which was the highest in all etiologies. Mean value of conjugated bilirubin was highest (0.7 mg/dL) in ABO incompatibility while unconjugated bilirubin level was highest in minor blood group incompatibility (17.6 mg/dL). G6PD deficiency had the highest maximum value of micro bilirubin (20.5 mg/dL) among other causes of neonatal jaundice. Only one blood film had a hypochromic picture and this was in the inconclusive diagnosis group. Almost all patients had a normal size of red blood cells. Anisocytosis accounted for 11.9% and microcytes were 3.4%. On the other hand, only 11% of newborns had a normal shape of red blood cells. The rest 89% of them had an abnormal shape such as poikilocytosis, burr cells, target cells, spherocyte, ovalocyte, schistocyte and polychromasia.

As shown in Table 5, the onset of jaundice was most commonly on the 2nd day after delivery (n=49; 41.9%). It was followed by the 3rd day after birth (n=35; 29.9%) and the 4th day (n=12; 10.3%). Early onset jaundice (within 24 hours after birth) was seen in 10 cases (8.5%) and most of them (70%) were inconclusive jaundice. One case of breastfeeding jaundice and 5

149 cases of inconclusive jaundice presented with late onset of jaundice on the 6th and 7th day of
 150 birth. Certain groups of infants who do not have significant jaundice during the first few days
 151 of life may develop hyperbilirubinemia later. Late-onset neonatal hyperbilirubinemia was
 152 defined as a total bilirubin level greater than 15 mg/dL or receiving phototherapy at 5-7 days.
 153 According to the onset of jaundice, treatment was started mostly on the 2nd day after birth.
 154 Duration of phototherapy ranged from 1 to 4 days. There were four cases that needed
 155 exchange transfusion therapy for rescue. One case was ABO incompatibility with the onset
 156 of jaundice on the second day of life, micro bilirubin level was 16.4 mg/dL and reticulocyte
 157 count was 14.9%. Three cases were inconclusive jaundice with the onset of jaundice on the
 158 2nd, the 4th and the 5th day and the micro bilirubin levels were 38.5, 32.9 and 31.1 mg/dL
 159 respectively, without evidence of haemolysis. For ABO incompatibility (n=21), all had blood
 160 group O mothers and blood group A and group B in newborn were 10 (47.6%) and 11
 161 (52.4%) respectively.

162 Table 6 shows that the mean value of the maximum and minimum haematocrit was
 163 significantly lower in the haemolysis group than in a non-haemolysis group (P= 0.013 and
 164 P<0.001). Nucleated red cells (NRC) count and percent of reticulocyte counts were higher in
 165 haemolysis group than in a non-haemolysis group and the difference was statistically
 166 significant. On the 1st day after delivery, that compatible with pathological jaundice and
 167 reticulocyte count was also increased (14.9% even on 1st day). Three cases were
 168 inconclusive jaundice with the onset of jaundice on the 2nd, the 4th and the 5th day and the
 169 micro bilirubin level are 38.5, 32.9 and 31.1 mg/dL respectively, without evidence of
 170 haemolysis.

171

172 Table 4: Laboratory profile according to the etiology of jaundice

Laboratory profile (Mean; Range; SD)	Blood group incompatibility		G6PD def. (n=5)	Breastfe eding (n=12)	Inconclusive (n=76)
	ABO (n=21)	Minor (n=2)			
CBC profile					
Maximum of Hct (%)	53.1 38-68 (7.3)	54.5 48-61 (9.2)	58.2 52-70 (7.2)	58.3 50-66 (5.9)	56.4 32-70 (6.7)
Minimum of Hct (%)	43.9 31-57 (7.4)	47.5 38-57 (13.4)	51.6 47-63 (6.5)	51.1 38-60 (6.6)	49.9 30-62 (7.1)
WBC count (X10 ³ /mm ³)	14.4 6.9-24.5 (4.7)	14.8 13.9-15.7 (1.3)	11.6 7.8-20.5 (5.1)	13.3 9.1-20.5 (3.6)	15.9 6.0-17.3 (23.3)
Platelet count (X10 ³ /mm ³)	291.0 145-494 (93.6)	345.5 314-377 (44.5)	234.8 165-357 (89.9)	236.3 66-398 (98.7)	275.8 89-599 (84.2)
NRC (/mm ³)	131.5 0-1470 (321.4)	0	0	0	9.9 0-232 (40.5)
% Reticulocyte count	8.6 3-14.9 (3.8)	13.6 3.5-23.6 (14.2)	4.6 2.8-8.0 (2.4)	7.1 0.7-13.4 (4.1)	6.0 0-15.1 (3.4)
Bilirubin					
Conjugated (mg/dL)	0.7 0.2-6.0	0.3 0.3-0.4	0.4 0.2-0.4	0.4 0.2-0.7	0.5 0.0-10.6

	(1.2)	(0.0)	(0.1)	(0.2)	(1.2)
Unconjugated (mg/dL)	16.0	17.6	16.6	15.6	16.8
	11.9-21.4	16.4-18.8	12.4-21.1	9.4-19.1	7.3-37.8
	(2.6)	(1.7)	(3.7)	(2.8)	(4.9)
Maximum of MB	17.4	18.1	20.5	17.1	18.3
	12.4-24.1	17.5-18.7	17.7-22.2	10.3-21.5	8.9-38.5
	(2.8)	(0.8)	(1.9)	(3.0)	(4.9)

173
174
175

Table 5: Onset and treatment of neonatal jaundice

Characteristic of jaundice	No.	Blood group incompatibility		G6PD def. (n=5)	Breastfeeding (n=12)	Cephal-hematoma (n=1)	Inconclusive (n=76)
		ABO (n=21)	Minor (n=2)				
ONSET OF JAUNDICE							
1 st day of birth	10	2	0	0	1	0	7
2 nd day of birth	49	14	1	4	6	0	24
3 rd day of birth	35	5	0	0	3	1	26
4 th day of birth	12	0	1	1	1	0	9
5 th day of birth	5	0	0	0	0	0	5
6 th day of birth	1	0	0	0	0	0	1
7 th day of birth	5	0	0	0	1	0	4
TREATMENT							
Day of start therapy							
1 st day of birth	10	2	0	0	1	0	7
2 nd day of birth	51	15	2	4	6	0	24
3 rd day of birth	32	3	0	0	3	0	26
4 th day of birth	11	0	0	1	1	0	9
5 th day of birth	4	0	0	0	0	0	4
6 th day of birth	3	1	0	0	0	0	2
7 th day of birth	4	0	0	0	1	0	3
8 th day of birth	2	0	0	0	0	1	1
Phototherapy duration (Days) (Mean; Range; SD)							
Single phototherapy	1.4	1	1.2	1.3	1	1.1	
	0-2		1-2	0-3		0-4	
	(0.6)		(0.4)	(0.9)		(0.7)	
Double phototherapy	0.5	1	0.8	0.3	0	0.5	
	0-2	0-2	0-1	0-1		0-2	
	(0.7)	(1.4)	(0.4)	(0.5)		(0.7)	
All type	1.9	2.0	2.0	1.7	1	1.6	
	1-4	1-3	1-3	1-4		1-6	
	(0.7)	(1.4)	(0.7)	(1.0)		(0.9)	

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

Table 6: Laboratory profile according to etiology of jaundice

Laboratory	Haemolysis (n=24)	Non- haemolysis (n=93)	P value
CBC profile			
Maximum of Hct (%)	53.0 38-68 (7.2)	56.8 32-70 (6.5)	0.013
Minimum of Hct (%)	44.2 31-57 (7.7)	50.1 30-63 (6.9)	<0.001
WBC count (X10 ³ /mm ³)	14.5 6.9-24.5 (4.4)	15.3 6.0-17.3 (21.2)	>0.05
Platelet count (X10 ³ /mm ³)	304.1 145-497 (98.1)	265.4 66-599 (83.4)	>0.05
NRC count (/mm ³)	115.0 0-1470 (303.0)	8.1 0-232 (36.8)	0.001
% Reticulocyte count	8.7 3.0-23.6 (4.9)	6.0 0-15.1 (3.5)	0.003
4. Bilirubin			
Conjugated (m/dL)	0.7 0.16-6.0 (1.2)	0.5 0-10.6 (1.1)	>0.05
Unconjugated (m/dL)	16.4 11.9-21.4 (2.7)	16.6 7.3-37.8 (4.6)	>0.05
Maximum of MB	17.6 12.4-24.1 (2.7)	18.2 8.9-38.5 (4.6)	>0.05

194

195

196

197

198

199

200

201

202

DISCUSSION

This study was conducted to describe the various clinical profiles of early neonatal jaundice. Careful history taking, physical examinations, early measurement of serum bilirubin and work up for jaundice was recorded to elicit the risk factors and different etiologies. According to the exclusion criteria of the current study, preterm babies with neonatal jaundice were not studied.

It is crucial to assess characteristic maternal and neonatal profile during the hospital stay and on discharge for risk of neonatal jaundice [16].

203 In our study, there was no difference between haemolysis and non-haemolysis group
204 according to spontaneous delivery which was similar to the previous study finding [17].
205 Increased frequency of jaundice is obviously associated with maternal usage of epidural
206 anaesthesia. We found that the minimum haematocrit was significantly lower and
207 reticulocyte count is significantly higher in the haemolytic group compared to the non-
208 haemolytic group which were compatible with the pathogenesis of hyperbilirubinemia. [18].

209 According to etiologies and maternal profile, nearly 50% of ABO incompatibility is
210 primigravida in this study which is similar to the previous study establishing that
211 approximately 50% of the ABO haemolytic jaundice cases occur in first-born infants and
212 there is no predictable pattern of recurrence in subsequent infants [19]. Rh haemolytic
213 disease and sepsis are etiologies that have increased the risk of bilirubin encephalopathy
214 than ABO incompatibility [20]. Previous research showed inconclusive jaundice was the
215 most common aetiology as demonstrated in our study.

216 Theoretically, G6PD deficiency usually occurs in males although heterozygous females
217 may manifest the mild features of disease [21]. In our study, newborns diagnosed as G6PD
218 deficiency were all males (4.2%).

219 Infection is one of the risk factors of hyperbilirubinemia [22]. Unexplained unconjugated
220 hyperbilirubinemia may be the first **sign** of neonatal sepsis as bacterial sepsis can contribute
221 to neonatal jaundice [23]. Our study did not demonstrate a higher WBC count in the non-
222 haemolytic group compared to the haemolytic group. One of the possible explanations was
223 that unidentified non-infectious etiologies may also play a significant role in the aetiology of
224 non-haemolytic jaundice.

225 Measuring serum bilirubin concentrations exactly 24hours after delivery or at a later time
226 just before discharge may improve the sensitivity of this predictor for hyperbilirubinemia [24].
227 Predictive bilirubin nomogram is an effective predictor for significant hyperbilirubinemia
228 according to their risks; high, intermediate and low [25].

229 Among four cases for whom exchange transfusion was done, one case was ABO
230 incompatibility and the rest three cases were inconclusive jaundice. Three cases of
231 inconclusive jaundice had no evidence of haemolysis and onset of jaundice were on 2nd, 4th
232 and 5th day while the micro bilirubin levels were 38.5, 32.9 and 31.1 mg/dL respectively. All
233 neonatal jaundice with high bilirubin levels would require aggressive treatment (such as
234 exchange transfusion and double phototherapy) to prevent complications of
235 hyperbilirubinemia [26]. In a newborn with bilirubin level above 20 mg/dL, there is a
236 noticeable association with kernicterus which has 70% long term consequences [27].
237

238 5. CONCLUSION

239
240 Among various etiologies of neonatal jaundice in term babies, the most common etiology
241 was inconclusive jaundice because it only relied on the medical record. Further septic works
242 up and investigations are required to identify the accurate diagnosis. As stated in other
243 studies and literature, the second common etiology was ABO incompatibility. Neonatal
244 jaundice caused by non-immune hemolysis and polycythemia were not found in this study.
245 High WBC count in inconclusive jaundice supports the possibility of neonatal sepsis and
246 infections that are also the main concern for neonatal jaundice. There is no decrease in the
247 mean values of platelet count. Mean value of reticulocyte count was highest in the diagnosis
248 of minor blood group incompatibility. There was a significant difference of haematocrit, NRC
249 and reticulocytes between haemolytic and non-haemolytic groups. As the study was the
250 hospital-based retrospective record study, the subjective data such as progression of
251 jaundice and other clinical findings were not observed. To retrieve the comprehensive data,
252 the prospective study is suggested. Our study has limitation to illustrate neonatal jaundice in
253 preterm and other conditions because it is only focused on babies born from 37 to 42 weeks.
254 As prematurity is one of the main cause of neonatal jaundice, further research with different
255 inclusion criteria is suggested.

256 Nevertheless, the study highlighted the etiologies of neonatal jaundice of study group,
257 laboratory profiles with significance in haemolysis, onset of jaundice and duration of different
258 managements.

259

260 **COMPETING INTERESTS**

261

262 Authors have declared that no competing interests exist.

263

264 **CONSENT**

265

266 NA

267

268 **ETHICAL APPROVAL**

269

270 This research was approved and funded by the Faculty of Tropical Medicine, Mahidol
271 University, Thailand.

272

273 **REFERENCES**

274

275 1. Mitra S, Rennie J. Neonatal jaundice: aetiology, diagnosis and treatment. *Br J Hosp*

276 *Med (Lond)*. 2017; 2; 78(12):699-704. doi: 10.12968/hmed.2017.78.12.699.

277 2. Brown AK. Bilirubin metabolism with special reference to neonatal jaundice. *Adv*
278 *Pediatr* 1962;12:121-87.

279 3. Watchko JF, Oksi FA. Bilirubin 20 mg/dl=vagintiphobia. *Pediatr*. 1983; 71: 660-3.

280 4. Olusanya BO, Teeple S, Kassebaum NJ. The Contribution of Neonatal Jaundice to
281 Global Child Mortality: Findings from the GBD 2016 Study. *Paediatrics*. 2018;
282 141(2). pii: e20171471. doi: 10.1542/peds.2017-1471

283 5. Lalitha KG. Neonatal jaundice. In: Ghai OP, Gupta P, Paul VK, editors. *Ghai*
284 *Essential Paediatrics*. 5th ed. New Delhi: Interprint; 1993.

285 6. Newman AJ, Gross S. Hyperbilirubinemia in breast fed infants. *Pediatr* 1983;
286 32:995-1000.

287 7. Newman TB, Klebanoff MA. Neonatal hyperbilirubinemia and long term outcome.
288 *Pediatr*. 1993; 92(5):651-7.

289 8. Phyllis AD, Daniel SS, David KS. Neonatal hyperbilirubinemia. *N Eng J Med*. 2001;
290 344(8): 211.

291 9. Campbell N, Harvey D, Norman AP. Increased frequency of neonatal jaundice in a
292 maternity hospital. *Br Med J*. 1976; 1:548-52.

293 10. CDC-MMWR (Morbidity and Mortality Weekly Report). Kernicterus in full term
294 infants- United States, 1994- 1998. 2001;50(23):491-4.

295 11. Anthony JP, Barbara JS. Jaundice and hyperbilirubinemia in newborn. In: Robert
296 MK, Richard EB, Hal BJ, editors. *Nelson Textbook of Pediatrics*.18th ed. London:
297 WB Saunders; 2007.

298 12. Chuniaud L, Dessante M, Chantoux F, Blondeau JP, Francon J, Trivin F.
299 Cytotoxicity of bilirubin for human fibroblasts and rat astrocytes in culture. *Clin Chim*
300 *Acta*. 2006; 256(2):103-14.

301 13. Bratlid D. How bilirubin gets into the brain. *Clin Perinatol*. 1990;17(2):449-65.

302 14. Pamela GL. Jaundice in the Newborn. In: Ronald MP, James DS, Dale AN, editors.
303 *Paediatric hospital medicine, Textbook of inpatient management*. Philadelphia:
304 Lippincott Williams & Wilkins; 2003.

- 305 15. Kuzniewicz MW, Wickremasinghe AC, Wu YW, McCulloch CE, Walsh EM, Wi S, et
306 al. Incidence, Etiology, and Outcomes of Hazardous Hyperbilirubinemia in
307 Newborns. *Paediatrics*. 2014; 134 (3). doi:10.1542/peds.2014-0987
308 16. Maisels MJ, Kring E. Length of stay, jaundice and hospital readmission. *Pediatric*.
309 1998; 101(6): 995-8.
310 17. Sarici SU, Yurdakok M, Serdar MA, Oran O, Erdem G, Tekinalp G, et al. An early
311 (sixth hour) serum bilirubin measurement is useful in predicting the development of
312 significant hyperbilirubinemia and severe ABO haemolytic disease in a selective
313 high risk population of newborns with ABO incompatibility. *Paediatric*. 2002; 109(4);
314 53.
315 18. David E. Neonatal Jaundice. *BMJ Clin Evid*. 2007; 12:319 -28.
316 19. Hinkes MT, Cloharty JP. Neonatal hyperbilirubinemia. In: Cloharty JP, Stork AR,
317 editors. *Manual of neonatal care*. 5th ed. Philadelphia: Lippincott Williams & Wilkins;
318 1998:175-211.
319 20. Gamaleldin R, Iskander I, Seoud I, Aboraya H, Aravkin A, Sampson PD, et al. Risk
320 Factors for Neurotoxicity in Newborns With Severe Neonatal Hyperbilirubinemia.
321 *Paediatrics*. 2011; 128(4): e925–e931. doi: [10.1542/peds.2011-0206]
322 21. Malcolm IL, David IT, Sunil S. Jaundice. In: Malcolm IL, David IT, Sunil S. editors,
323 *Essential Neonatal Medicine* 4th ed. Oxford: Blackwell Publishing; 2008: 130-41.
324 22. Rennie JM, Robertson NRC. Physiological jaundice. In: Rennie JM, Robertson NRC,
325 editors. *A manual of neonatal intensive care*. 4th ed. London, 2002: 419.
326 23. Lindar N, Yatsiv I, Tsur M, Matoth I. Unexplained neonatal jaundice as an early
327 diagnostic sign of septicemia in the newborn. *Journal of Perinatology*. 8(4):325-7.
328 24. Seidman DS, Shaltiel ZE, Paz I, Gale R. Predicting the Risk of Jaundice in full term
329 Healthy Newborns: A Prospective Population-Based Study. *Journal of Perinatology*.
330 1999; 19(8): 564-7.
331 25. Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific
332 serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and
333 near-term newborns. *Paediatrics*. 1999; 103(1):6-14.
334 26. Tan KL. Neonatal Jaundice. In: Robinson MJ and Lee EL editors. *Paediatric*
335 *Problems in Tropical Countries*. 2nd ed. London. Dr. K C Chaudhuri Foundation;
336 1983: 91-8.
337 27. Ip S, Chung M, Kulig J, O'Brien R, Sege R, Glicken S, et al. An evidence-based
338 review of important issues concerning neonatal hyperbilirubinemia. *Paediatrics*.
339 2004; 114(1):e130-53.PMID: 15231986.
- 340 28. Maria Fernanda B. de Almeida . When should we start phototherapy in preterm
341 newborn infants? *J. Pediatr. (Rio J.)* vol.80 no.4 Porto Alegre July/Aug. 2004.
342

343
344
345
346

DEFINITIONS, ACRONYMS, ABBREVIATIONS

Here is the Definitions section. This is an optional section.

Term: Definition for the term